Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 45

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 45
---
 |     |   |   — |     |   |   3 |     |   |   7 |     |   |     — |   |     |   |    10 |
| Impairment losses for the year                                  |     |   |   — |     |   |  11 |     |   |   — |     |   |       | 0 |     |   |    11 |
| Amortization and impairment losses at the end of the year       |     |   |   — |     |   | 126 |     |   |   7 |     |   |     — |   |     |   |   133 |
| Carrying amount at the end of the year                          |     | $ | 355 |     | $ |  23 |     | $ | 173 |     | $ | 1,532 |   |     | $ | 2,083 |

Other Intangible Assets

The increase in the gross carrying value of other intangible assets during the first six months of 2025 was due to the addition of $ 32million of licenses and patents.

Amortization expense was $ 7million and $ 4million for the first six months of 2025 and 2024 respectively, which was recorded in Research and development expenses in the Condensed Consolidated Statements of Comprehensive Income.

Goodwill

The carrying amount of goodwill, which relates to the acquisition of ProfoundBio during the second quarter of 2024, was $ 355million as of both June 30, 2025 and December 31, 2024.

Note 5 - Financial Instruments

Genmab’s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab’s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities were as follows:

|         |     |     | June 30, 2025 |     |   |     |     | December 31, 2024 |     |   |
|:--------|:----|:----|--------------:|:----|:--|:----|:----|------------------:|:----|:--|
| Percent |     |     |               |     |   |     |     |                   |     |   |
| USD     |     |     |            75 |     | % |     |     |